protein of endothelial cells and platelets and expressed on the cell surface following exposure to thrombin, histamine or complement components. This adhesion molecule mediates the recruitment of neutrophils to sites of inflammation and the attachment of myelomonocytes to platelets. CD62, like other members of the selectin family, possesses a lectin motif at the extracellular domain which is postulated to recognize the carbohydrate ligands. Fucosyl N-acetyllactosamine(CD15, Lewisx determinant) has been advanced as one of the candidates (Larsen, S. et al, Cell63, 467-474,1990 ), but sialic acid might also be involved in CD62 ligand (Moore, K.L. et al., J. Cell. Biol. 112, (491) (492) (493) (494) (495) (496) (497) (498) (499) . This paper shows that CD62 binds to sulfatide on granulocytes and tumor cells. It also demonstrated that granulocytes excrete sulfatide at a rate that allows them to get rid of endothelial cells.
First, CD62 soluble protein chimeras were prepared by genetic fusion of the extracellular domains of CD62 to the human IgGl. This soluble CD62 was called CD62Rg. This
CD62Rg was successfully applied to analyze the binding between CD62Rg and target cells (or ligands). Studies using flow cytometry showed CD62Rg reacts with a cell surface ligand on freshly isolated human granulocytes and human myelogenous leukemia cell line HL60. Interestingly, CD62Rg binds to breast carcinoma cell lines H3630 and H3396. However, cell surface binding was not observed with leukemic T cell lines, melanoma cells and murine fibroblast cells. The lipid extracts of HL60 cells were subjected to thin layer chromatography (TLC) and incubated with the radiolabeled CD62, followed by fluorography. Suflatide, 3-sulfated galactosyl ceramide, of HL60 cells reached strongly with CD62. Neither glycolipids bearing CD 15 nor gangliosides from a bovine brain were detected to react with CD62Rg under the conditions used. Lysosulfatide, lacking the fatty acyl substitution, was not recognized, either. This is not explained according to the primary structure of the sugar chain. Aglycon(iipid) portion may have influenced the three dimensional structure of the glycosphingolipid on a TLC plate. The authors determined whether sulfat-ides could be detected on the plasma membrane of granulocytes and tumor cell lines with the help of a monoclonal antibody, sulph 1. Neutrophils and breast carcinoma cell lines which were strongly reactive with CD62Rg, expressed cell surface sulfatide, while other non-reactive cell lines did not. Incubation of HL 60 cells in a medium containing sodium selenate, an inhibitor of sulfation, resulted in a reduction of expression of sulfatide and CD62-reactivity. The most striking finding in this paper is the sulfatide excretion by granulocytes, myeloid and tumor cells. The data indicate that human granulocytes excrete at least 50 fg of sulfatide per cell within 12 hr. According to the authors, the concentration of sulfatide could quickly (i.e. in less than 5 min) rise to adhesion-inhibiting concentrations.
In summary, myeloid cells bind to CD62(P-selectin) expressed on endothelial cells. This recognition system includes the specific binding between CD62 and sulfatide and/or CD15(Lewisx). Granulocytes excrete sulfatide at sufficient rate to allow them to be rapidly released from their receptors(CD62) as the cell traverses the endothelial cell junction.
CD62 interaction with sulfatides may also influence pathological interactions between tumor cells and endothelium, this being quite significant for understanding the mechanism for tumor metastasis.
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